<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="jia225048-tbl-0002" xml:lang="en" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Trial research methodologies</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">Trial</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Countries</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Design</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Primary objective</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Primary outcome</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Study power</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Coefficient of variation between clusters </th>
    <th align="left" valign="top" rowspan="1" colspan="1">Estimated trial impact</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Duration (average follow‐up)
     <xref ref-type="fn" rid="jia225048-note-0007">a</xref>
    </th>
    <th align="left" valign="top" rowspan="1" colspan="1">Estimated completion date</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">BCPP</td>
    <td align="left" rowspan="1" colspan="1">Botswana</td>
    <td align="left" rowspan="1" colspan="1">2 arm community‐level pair‐matched cluster‐randomized trial</td>
    <td align="left" rowspan="1" colspan="1">To evaluate whether expanded ART initiation (initially by high HIV‐1 RNA level and higher CD4 threshold, now universal ART), combined with strengthened and expanded HIV testing/linkage and male circumcision services, can significantly reduce cumulative HIV incidence at population‐level, in 16 to 64 year old community residents in Botswana.</td>
    <td align="left" rowspan="1" colspan="1">Cumulative HIV incidence</td>
    <td align="left" rowspan="1" colspan="1"> 86% (original parameters and ART initiation criteria)
     <break/> 72% (revised parameters based on observed data, and actual ART initiation criteria over time) 
    </td>
    <td align="left" rowspan="1" colspan="1">0.26</td>
    <td align="left" rowspan="1" colspan="1">40% reduction of cumulative HIV incidence in the intervention arm</td>
    <td align="left" rowspan="1" colspan="1"> 60 months
     <break/> (average follow‐up of 36 months) 
    </td>
    <td align="left" rowspan="1" colspan="1">October 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <italic>Max</italic>ART
    </td>
    <td align="left" rowspan="1" colspan="1">Swaziland</td>
    <td align="left" rowspan="1" colspan="1">2 arm clinic‐catchment level ‐ stepped‐wedge cluster‐randomized trial </td>
    <td align="left" rowspan="1" colspan="1">To evaluate whether early ART initiation for all HIV+ individuals can improve retention and viral suppression at population‐level, in over 18‐year‐olds, in Swaziland's government‐managed health system.</td>
    <td align="left" rowspan="1" colspan="1">Retention and viral suppression</td>
    <td align="left" rowspan="1" colspan="1">80% </td>
    <td align="left" rowspan="1" colspan="1">0.5</td>
    <td align="left" rowspan="1" colspan="1">6% increase in 1‐year retention rate between the control phase and intervention phase</td>
    <td align="left" rowspan="1" colspan="1">36 months</td>
    <td align="left" rowspan="1" colspan="1">August 2017</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">PopART</td>
    <td align="left" rowspan="1" colspan="1">South Africa, Zambia </td>
    <td align="left" rowspan="1" colspan="1">3 arm community‐level triplet‐matched cluster‐randomized trial</td>
    <td align="left" rowspan="1" colspan="1">To determine the impact of two community‐level combination prevention packages, both of which include universal HIV testing and intensified provision of HIV ART and care, on population‐level HIV incidence</td>
    <td align="left" rowspan="1" colspan="1">Cumulative HIV incidence </td>
    <td align="left" rowspan="1" colspan="1"> &gt;99% for Arm A versus Arm C comparison (original model parameters and ART initiation criteria);
     <break/> In range 44% to 95% for Arm A versus Arm C comparison (revised parameters based on trial data including on testing and treatment coverage over time) 
    </td>
    <td align="left" rowspan="1" colspan="1">0.15 to 0.2</td>
    <td align="left" rowspan="1" colspan="1"> 60% to 65% reduction in HIV incidence in arm A in years 2 and 3 of intervention (original parameters and ART initiation criteria);
     <break/> 35% to 45% reduction of HIV incidence in arm A in years 2 and 3 of intervention (revised parameters) 
    </td>
    <td align="left" rowspan="1" colspan="1"> 54 months
     <break/> (average follow‐up of 36 months) 
    </td>
    <td align="left" rowspan="1" colspan="1">June 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">SEARCH</td>
    <td align="left" rowspan="1" colspan="1">Uganda, Kenya</td>
    <td align="left" rowspan="1" colspan="1">2 arm 2 phase community‐level pair‐matched cluster‐randomized trial</td>
    <td align="left" rowspan="1" colspan="1"> Phase 1: To quantify the impact of early HIV diagnosis and immediate ART using a streamlined care delivery system on the three‐year cumulative HIV incidence among adults aged ≥15 years old in rural communities in Uganda and Kenya
     <break/> Phase 2: To quantify the impact of targeted PrEP, targeted HIV testing and targeted care interventions on top of universal treatment and streamlined care on the 3‐year cumulative HIV incidence among adults aged ≥15 years old in rural communities in Uganda and Kenya 
    </td>
    <td align="left" rowspan="1" colspan="1">Cumulative HIV incidence</td>
    <td align="left" rowspan="1" colspan="1">80% in both Phase1 and Phase2</td>
    <td align="left" rowspan="1" colspan="1">≤0.4</td>
    <td align="left" rowspan="1" colspan="1">40% reduction in cumulative HIV incidence (both Phase 1 and 2) in the intervention arm</td>
    <td align="left" rowspan="1" colspan="1"> 72 months
     <break/> (follow‐up of 36 months in Phase 1 and 36 months in Phase 2) 
    </td>
    <td align="left" rowspan="1" colspan="1"> June 2017 for Phase1
     <break/> June 2020 for Phase2 
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">ANRS TasP</td>
    <td align="left" rowspan="1" colspan="1">South Africa</td>
    <td align="left" rowspan="1" colspan="1">2 arm community‐level cluster‐randomized trial</td>
    <td align="left" rowspan="1" colspan="1"> Phase 1: To estimate the feasibility and acceptability of early ART initiation for all HIV+ individuals combined with six monthly home‐based HIV testing of all adult members of a community and linkage‐to‐care services at population‐level in 16 and above years of age, in KwaZulu‐Natal province in South Africa.
     <break/> Phase 2: To compare how early ART initiation for all HIV+ individuals combined with six monthly home‐based HIV testing of all adult members of a community and linkage‐to‐care services can impact on the reduction in incidence of new HIV infections at population‐level in 16 and above years of age, in KwaZulu‐Natal province in South Africa. 
    </td>
    <td align="left" rowspan="1" colspan="1">Cumulative HIV incidence</td>
    <td align="left" rowspan="1" colspan="1">80%</td>
    <td align="left" rowspan="1" colspan="1">0.25</td>
    <td align="left" rowspan="1" colspan="1">A 34% reduction in cumulative HIV incidence in the intervention arm</td>
    <td align="left" rowspan="1" colspan="1"> 52 months
     <break/> (average follow‐up of 36 months) 
    </td>
    <td align="left" rowspan="1" colspan="1"> June 2014 for Phase 1
     <break/> July 2016 for Phase 2 
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="jia225048-note-0006">
   <p>ART, antiretroviral therapy; PrEP, pre‐exposure prophylaxis.</p>
  </fn>
  <fn id="jia225048-note-0007">
   <label>a</label>
   <p>The trial duration refers to the period between the first day an intervention was provided to a study participant and the last day an intervention was provided to a study participant. The average follow‐up refers to the average time a study participant was observed in the context of the trial.</p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
 </permissions>
</table-wrap>
